Bapineuzumab and Placebo (IMAGE)

Brown University

Bapineuzumab and Placebo

Caption

DAD (Disability Assessment for Dementia) scores worsened on average during the 78-week trial, with "bapi" (dotted blue line) showing no improvement over placebo. This data is from the trial with APOE allele carriers.

Credit

Salloway et. al.

Usage Restrictions

with credit

License

Licensed content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.